OBJECTIVE: To determine whether captopril alters peripheral venous tone in patients with congestive cardiac failure. DESIGN: Open study of patients at start of captopril treatment and three months later. SETTING: A hospital gamma camera laboratory. PATIENTS: 16 Men with congestive cardiac failure in New York Heart Association class II or III, aged 57-73. INTERVENTIONS: Patients were initially given 500 micrograms sublingual glyceryl trinitrate followed by 25 mg oral captopril. The study was then repeated after three months' captopril treatment. MAIN OUTCOME MEASURES: Previously validated non-invasive radionuclide techniques were used to measure changes in central haemodynamic variables and peripheral venous volumes in the calf. RESULTS: After 25 mg captopril there were falls in blood pressure and relative systemic vascular resistance and increases in cardiac index and left ventricular ejection fraction. This was accompanied by a 16% increase in peripheral venous volume (95% confidence interval 13.4% to 18.4%, p less than 0.01), which compared with an 11% increase after 500 micrograms glyceryl trinitrate (10% to 12%, p less than 0.01). Eleven patients were restudied after three months' continuous treatment with captopril. The resting venous volume was higher than it had been initially, by about 10%, and increased by a further 8.4% after 25 mg captopril (5.4% to 11.4%, p less than 0.05). CONCLUSIONS: Captopril is an important venodilator. Venous and arterial dilatation are produced short term and during long term treatment.
OBJECTIVE: To determine whether captopril alters peripheral venous tone in patients with congestive cardiac failure. DESIGN: Open study of patients at start of captopril treatment and three months later. SETTING: A hospital gamma camera laboratory. PATIENTS: 16 Men with congestive cardiac failure in New York Heart Association class II or III, aged 57-73. INTERVENTIONS:Patients were initially given 500 micrograms sublingual glyceryl trinitrate followed by 25 mg oral captopril. The study was then repeated after three months' captopril treatment. MAIN OUTCOME MEASURES: Previously validated non-invasive radionuclide techniques were used to measure changes in central haemodynamic variables and peripheral venous volumes in the calf. RESULTS: After 25 mg captopril there were falls in blood pressure and relative systemic vascular resistance and increases in cardiac index and left ventricular ejection fraction. This was accompanied by a 16% increase in peripheral venous volume (95% confidence interval 13.4% to 18.4%, p less than 0.01), which compared with an 11% increase after 500 micrograms glyceryl trinitrate (10% to 12%, p less than 0.01). Eleven patients were restudied after three months' continuous treatment with captopril. The resting venous volume was higher than it had been initially, by about 10%, and increased by a further 8.4% after 25 mg captopril (5.4% to 11.4%, p less than 0.05). CONCLUSIONS:Captopril is an important venodilator. Venous and arterial dilatation are produced short term and during long term treatment.
Authors: J G Cleland; H J Dargie; G P Hodsman; S G Ball; J I Robertson; J J Morton; B W East; I Robertson; G D Murray; G Gillen Journal: Br Heart J Date: 1984-11
Authors: J N Cohn; D G Archibald; S Ziesche; J A Franciosa; W E Harston; F E Tristani; W B Dunkman; W Jacobs; G S Francis; K H Flohr Journal: N Engl J Med Date: 1986-06-12 Impact factor: 91.245
Authors: N D Holman; O S Hoekstra; A B Groeneveld; A J Schneider; W G de Voogt; J van der Meer Journal: Eur J Clin Pharmacol Date: 1994 Impact factor: 2.953